Command Palette

Search for a command to run...

Clinical Trials · NCT03315780

A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes

CompletedPhase 4Dulaglutide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
12
Start date
Oct 2017
Locations
1 site, Japan
Primary endpoint
Change From Baseline in Glucose Area Under the Concentration Versus Time Curve From Time Zero to 4 Hours (AUC[0-4h])
View Dulaglutide compound reference